CD20, monoclonal antibody

McLaughlin P, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma Half of patients respond to a four dose treatment program. J Clin Oncol 1998 16 2825-2833. 

Rituxan (anti-CD20 monoclonal antibody) Liquid for IV injection Store at 2-8°C protect from light lOOmg or 500mg vial 9.0mg/mL NaCl, 7.35mg/mL Na-citrate, 0.7 mg/mL polysorbate 80... 

H. Gazzano-Santoro, P. Ralph, T. Ryskamp, A. Chen, and V. Mukku, A non-radioactive complement-depen-dent cytotoxicity assay for anti-CD20 monoclonal antibody, J. Imunol. Methods, 202, 163 (1997). 

Bonner, J.A. et al., Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck a phase III study of high dose radiation therapy with or without cetuximab, Proc. Am. Soc. Clin. Oncol., 22, 489S, Abstr. 5507, 2004. McLaughlin, R et al., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma half of patients respond to a four-dose treatment program, /. Clin. Oncol., 16, 2825-2833, 1998. 

Polyak, M. and Deans, J., Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood, 99, 3256-3262, 2002. 

Cartron, G., Dacheux, L., Salles, G., Solal-Celigny R, Bardos, R, Colombat, R, and Watier, H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcyRllla gene. Blood, 99, 754—758, 2002. 

Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.-M., Dallaire, B.K., Wey K., Royston, I., Davis, T., and Levy, R., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin s lymphoma. Blood, 90, 2188-2195, 1997. 

Van Oers, M.H., Hagenbeek, A., Van Glabbeke, M., and Teodorovic, L, Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin s lymphoma a phase III randomized clinical trial — Intergroup Collaborative Study, Ann. HematoL, 81, 553-557, 2002. 

Examples of antibodies in the market include trastuzumab (anti-HER2 monoclonal antibody), rituximab, natalizumab (x4-integiin antibody), abciximab, infiximab (targets TNF-a in Crohn s disease and rheumatoid arthritis), alemtuzumab, adalimumab (TNF-a antibody for the treatment of rheumatoid arthritis) and efalizumab (anti-CDlla monoclonal antibody for the treatment of psoriasis)Rituximab is a mouse/human chimeric anti-CD20 monoclonal antibody used for the treatment of various l)unphoid malignancies. As CE)20 antigen is found on the surface of... 

Anti-CD20 monoclonal antibody [SY] IDEC-C2B8 [SY]... 

CD20 monoclonal antibody, recombinant [SY] MabThera [TR used by Roche outside of US and Japan]... 

Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000 95 3900-3908. 

Bowles JA, Wang SY, Link BK et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK eells at lower eoneentrations and more effectively than rituximab. Blood... 

Tositumomab is another anti-CD20 monoclonal antibody and is complexed with iodine 131 (131I). Tositumomab is used in two-step therapy in patients with CD20-positive, follicular non-Hodgkin s lymphoma whose disease is refractory to rituximab and standard chemotherapy. Toxicities are similar to those for ibritumomab and include severe cytopenias such as thrombocytopenia and neutropenia. Tositumomab should not be administered to patients with greater than 25% bone marrow involvement. 

Boyne J, Elter T, Engert A. 2003. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. 14 520-535. 

Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, et al. 2005. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am... 

Song H, Du Y, Sgouros G, Prideaux A, et al. 2007. Therapeutic potential of 90Y and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin s lymphoma with pulmonary involvement. JNM. 48 150-157. 

Combination chemotherapy is the treatment standard for patients with diffuse non-Hodgkin s lymphoma. The anthracycline-containing regimen CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) has been considered the best treatment in terms of initial therapy. Recently, randomized phase III clinical studies have shown that the combination of CHOP with the anti-CD20 monoclonal antibody rituximab results in improved response rates, disease-free survival, and overall survival compared with CHOP chemotherapy alone. 

Cznczman, M. S., Grillo-Lopez, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., and Varns, C. (1999). Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy./ Clin Oncol. 17, 268-276. 

CoilHer, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J. A., Capdeville, R., Diehl, V., and Reyes, F. (1998). Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma A multicenter phase II study. Blood 92,1927-1932. 

Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999 94(7) 2217-24. 

With the broadening of the therapeutic applications of biopharmaceuticals, new safety issues can be anticipated in the future. Since the late nineties, ritux-imab (anti-CD20 monoclonal antibody) has been used to treat non-Hodgkin s... 

Immunoconjugate murine anti-CD20 monoclonal antibody + Y90 + In111 reacts with normal and malignant B lymphocytes... 

Hagberg H, Lundhohn L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001 115(3) 609-11. 

---